| The Management of Neuroendocrine Tumours: Current and Future Medical Therapy Options. | |
| | |
MedLine Citation:
|
PMID: 21907552 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Neuroendocrine tumours (NETs) are a genetically diverse group of malignancies that sometimes produce peptides causing characteristic hormonal syndromes. NETs can be clinically symptomatic (functioning) or silent (non-functioning); both types frequently synthesise more than one peptide, although often these are not associated with specific syndromes. Based on data from various sources, the incidence and prevalence of NETs is increasing. The primary treatment goal for patients with NETs is curative, with symptom control and the limitation of tumour progression as secondary goals. Surgery is the only possible curative approach and so represents the traditional first-line therapy. However, as most patients with NETs are diagnosed once metastases have occurred, curative surgery is generally not possible. Patients therefore require chronic postoperative medical management with the aim of relieving symptoms and, in recent years, suppressing tumour growth and spread. Somatostatin analogues, such as octreotide long-acting repeatable (LAR), can improve the symptoms of carcinoid syndrome and stabilise tumour growth in many patients. Results from the PROMID study show that octreotide LAR 30mg is an effective antiproliferative treatment in patients with newly diagnosed, functionally active or inactive, well-differentiated metastatic midgut NETs. An antiproliferative effect can also be achieved with everolimus, and combination therapy with octreotide LAR has shown synergistic antiproliferative activity. In the future, pasireotide, the multi-receptor targeted somatostatin analogue, has the potential to be an effective therapy for de novo or octreotide-refractory carcinoid syndrome and for inhibiting tumour cell proliferation. Peptide receptor radiotherapy with [90]yttrium-DOTATOC or [177]lutetium-DOTATE is also a new interesting treatment option for NETs. |
| | |
Authors:
|
K E Oberg |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-9-8 |
Journal Detail:
|
Title: Clinical oncology (Royal College of Radiologists (Great Britain)) Volume: - ISSN: 1433-2981 ISO Abbreviation: - Publication Date: 2011 Sep |
Date Detail:
|
Created Date: 2011-9-12 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9002902 Medline TA: Clin Oncol (R Coll Radiol) Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2011 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved. |
Affiliation:
|
Department of Endocrine Oncology, University Hospital, SE-751 85 Uppsala, Sweden. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Electrochemically selective determination of dopamine in the presence of ascorbic and uric acids on ...
Next Document: Direct costs in diabetic and non diabetic people: The population-based Turin study, Italy.